Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Sees Significant Increase in Short Interest

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw a large increase in short interest during the month of April. As of April 30th, there was short interest totaling 423,802 shares, an increase of 4,053.7% from the April 15th total of 10,203 shares. Based on an average daily volume of 535,230 shares, the days-to-cover ratio is currently 0.8 days. Currently, 0.0% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on CHGCY shares. Smbc Nikko Sec. raised shares of Chugai Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, February 25th. UBS Group raised shares of Chugai Pharmaceutical to a “strong-buy” rating in a research note on Tuesday, January 27th. Two equities research analysts have rated the stock with a Strong Buy rating, Based on data from MarketBeat, the company has a consensus rating of “Strong Buy”.

Chugai Pharmaceutical Stock Performance

Shares of OTCMKTS CHGCY traded down $0.10 during trading on Monday, hitting $25.32. 182,183 shares of the company were exchanged, compared to its average volume of 238,819. Chugai Pharmaceutical has a 12-month low of $19.50 and a 12-month high of $34.84. The company has a fifty day moving average price of $28.11 and a 200-day moving average price of $27.17. The firm has a market capitalization of $83.34 billion, a PE ratio of 28.13 and a beta of 0.63.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings results on Friday, April 24th. The company reported $0.22 EPS for the quarter. Chugai Pharmaceutical had a return on equity of 22.40% and a net margin of 34.98%.The business had revenue of $2.05 billion for the quarter.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.